ArticleBMC cancer2018
Trends in pancreatic adenocarcinoma incidence and mortality in the United States in the last four decades; a SEER-based study.
Article in BMC cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05511116 (Neoadjuvant Treatment of Resectable or Locally Advanced Borderline Pancreatic Adenocarcinoma), which is not on this map. Cited by 153 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neoadjuvant Treatment of Resectable or Locally Advanced Borderline Pancreatic Adenocarcinoma: Reproducibility of Tumor Measurement in CT Versus MRI
Who cites it
153 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- A systematic review of prognosis predictive role of radiomics in pancreatic cancer: heterogeneity markers or statistical tricks?European radiology · 2022Pooled it
- Pooled it
- Targeting pancreatic cancer with adenoviral vectors equipped with transgenes.Molecular cancer therapeutics · 2026Article
- The PancreaSure Multianalyte Blood Test Performs Well at Distinguishing Early-Stage Pancreatic Ductal Adenocarcinoma from High-Risk Controls: A Retrospective Secondary Analysis.Journal of clinical medicine · 2026Article
- Acylglycerol kinase contributes to cell proliferation by activating NF‑κB signaling pathway in pancreatic cancer.Oncology reports · 2026Article
- Trends in Pancreatic Cancer Incidence, Mortality and Net Survival: A Population-Based Analysis in Zurich (Switzerland), 1981-2021.Journal of gastrointestinal cancer · 2026Article
- Progress and challenges in the development of advanced pancreatic cancer organoids.Journal of experimental & clinical cancer research : CR · 2026Review
- Real-world treatment outcomes for pancreatic neuroendocrine tumours: a single tertiary referral institute experience.ESMO gastrointestinal oncology · 2026Article
- Loss of Regulator of G Protein Signaling 11 Promotes Protumorigenic Features in Pancreatic Cancer.Molecular cancer research : MCR · 2026Article
- Detection and Classification of Pancreatic Cancer Nodules on CT Images using U-Net and Ensemble Models.Current medical imaging · 2026Article
- Cyclooxygenases in pancreatic ductal adenocarcinoma: are they inflammatory catalysts for tumor growth.Frontiers in oncology · 2026Review
- Shifting epidemiology of pancreatic cancer in Southeast Spain (1983-2018): emerging patterns in younger women and neuroendocrine neoplasms.Frontiers in oncology · 2026Article
- Analytical Validation of a Serum Biomarker Signature for Detection of Early-Stage Pancreatic Ductal Adenocarcinoma.Diagnostics (Basel, Switzerland) · 2025Article
- Confirmatory Clinical Validation of a Serum-Based Biomarker Signature for Detection of Early-Stage Pancreatic Ductal Adenocarcinoma.Current oncology (Toronto, Ont.) · 2025Article
- Circulating miRNAs as Non-Invasive Biomarkers in Pancreatic Cancer: A Two-Phase Plasma-Based Study.Journal of clinical medicine · 2025Article
- Article
- Higher Neutrophil-to-Lymphocyte Ratio and Systemic Immune-Inflammation Index Is Associated with Better Prognosis Following Pancreaticoduodenectomy for Pancreatic Adenocarcinoma.Journal of clinical medicine · 2025Article
- Incidence Trends in Upper Gastrointestinal Cancer in Young Adults: A Nationwide Time-Trend Analysis Using 2001-2019 US Cancer Statistics Databases.The American journal of gastroenterology · 2025Article
- Bibliometric review of journal articles on pancreatic cancer: insights into productivity and impact.Annals of pancreatic cancer · 2025Article
- Disparities in Gastrointestinal Cancer Incidence in Asian American, Native Hawaiian, and Other Pacific Islander Groups.Gastro hep advances · 2025Article
93 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPancreatic cancer is the fourth-leading cause of cancer deaths in the United States. The silent nature of the disease and its poor prognosis, the need for further research, along with the need to assess the outcomes of current approaches necessitate an ongoing evaluation of the epidemiology and mortality-trends of this malignancy. Continuous monitoring of disease-patterns, on population-levels, may help scientists assess the quality of healthcare delivery, boost their understanding of diseases' characteristics and risk factors, and detect gaps whereby further research is needed. None of the previous reports shed light on pancreatic adenocarcinomas (PAC), the most common type of Pancreatic Cancer, as the primary outcome. In this study we aim to investigate PAC's incidence and mortality trends over the last four decades in the United States.
methodsWe used SEER 9 database to study PAC cases during 1974-2014. Incidence and mortality rates were calculated by sex, age, race, state and stage of PAC. Annual percent change (APC) was calculated using joinpoint regression software.
resultsWe reviewed 67,878 PAC cases; most of these cases were in the head of pancreas. Overall PAC incidence rates increased 1.03% (95% CI, 0.86-1.21, p <.001) per year over the study period. Rates of adenocarcinoma of the head of pancreas increased 0.87% (95% CI, 0.68-1.07, p <.001), and rates of adenocarcinoma of the body and tail of pancreas increased 3.42% (95% CI, 3.06-3.79, p <.001) per year during 1973-2014. PAC incidence-based mortality increased 2.22% (95% CI, 1.93-2.51, p <.001) per year. However, during 2012-2014 there was a statistically significant decrease in PAC incidence-based mortality; APC, -24.70% (95% CI, -31.78 - -16.88, p <.001).
conclusionPAC's incidence and mortality rates have been increasing for decades. However, the last few years have shown a promising decrease in mortality. We believe that further advances in healthcare delivery and research can lead to a further mortality decrease. Future studies can use this paper as a baseline to keep monitoring the outcomes of PAC's therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.